78 results
20-F
2020 FY
EX-2.4
IMCR
Immunocore Holdings plc
25 Mar 21
Annual report (foreign)
7:01am
of Directors
Under the Companies Act, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple majority … .
Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares
6-K
IMCR
Immunocore Holdings plc
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
in these active dose cohorts were enrolled without prospective PRAME testing. In these patients, PRAME expression was analyzed retrospectively; the vast majority … tumor types had a best RECIST response of stable disease or progressive disease. A majority of patients evaluable for circulating tumor DNA had at least
F-3ASR
IMCR
Immunocore Holdings plc
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
resolution (which is passed by a simple majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service … cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (a) unless the certificate of incorporation
F-3ASR
EX-4.4
IMCR
Immunocore Holdings plc
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
and the Trustee by the holders of at least a majority in aggregate principal amount of the Securities of that series at the time Outstanding;
(4 … due and payable, either the Trustee or the holders of at least a majority in aggregate principal amount of the Securities of that series
424B7
IMCR
Immunocore Holdings plc
5 May 22
Prospectus with selling stockholder info
12:00am
majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service contract the director has … or in writing.
Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority
6-K
EX-99.1
g74rba1a0d6
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
424B7
xpvia04j3et2x7s
30 Sep 22
Prospectus with selling stockholder info
4:15pm
6-K
EX-99.1
2d4yeqk65e7
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
424B5
2gbpwiu9ano5 wjr0
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.1
f5h0ylp 7y
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
424B7
q0olscyl
5 Apr 24
Prospectus with selling stockholder info
4:34pm
S-3ASR
zvn9so1l6ucc7f
20 Mar 24
Automatic shelf registration
8:51pm
F-1/A
EX-99.1
b79cl dj8x2dyr5
1 Feb 21
Registration statement (foreign) (amended)
6:21am
6-K
u97pcw
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.2
ie4pfjos4w6wteem1
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.1
91e9to d2
20 Jul 22
Securities Purchase Agreement
4:06pm
8-K
EX-99.2
p8cad0
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.2
7baknthwnd hsc4ow
10 Aug 23
Current report (foreign)
8:28am
PRE 14A
cfobgl9niz081fuf
2 Apr 24
Preliminary proxy
4:45pm
DEF 14A
ei5kg y74u
12 Apr 24
Definitive proxy
4:20pm